Largest-ever Ozempic and GLP-1 drug study finds they lower risk of 42 health conditions, including heart attacks and Alzheimer’s disease
The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 receptor agonists.
Read Full Article on FortuneMENTIONED STOCKS
More Finance News
FBI thwarts ‘radicalized young man’ after undercover sting operation where he bought an assault rifle to attack the Mall of America
Drugs like Ozempic and Wegovy are linked to a lower risk of Alzheimer’s disease, new study says
Trump’s $2 billion midterms health-care bribe will go to just 20.8 million Americans, less than one-third of Medicare recipients
Trump administration wants schools to pay $70,000 fee for each international student in the OPT work program, as new foreign enrollment falls 17%
Four tribes partner with Kalshi to launch prediction apps–a move that undercuts Native American opposition to the industry
Content sourced from Fortune. Not financial advice.